Prof.  

Richard Langley

, Canada


Presentations

Consistent Response to Guselkumab by Disease Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial 10 October 2019 09:00 - 09:10 More ...
Consistency of Response by Disease Severity Characteristics in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From ECLIPSE Study 09 October 2019 00:00 - 00:00 More ...

Abstracts

Consistent Response to Guselkumab by Disease Region at Week 48 in the Treatment of Moderate to Severe Psoriasis: Results From the ECLIPSE Trial Psoriasis More
Consistency of Response by Disease Severity Characteristics in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab vs. Secukinumab: Week 48 Results From ECLIPSE Study Psoriasis More